CAR-T cell therapy for severe inflammatory bowel disease
Part of Digestive system clinical trials.
This trial tests a new treatment using modified immune cells (CAR-T cells) to reduce inflammation in people with moderate to severe inflammatory bowel disease (IBD) that hasn't improved with other advanced treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old and weigh at least 40 kg.
- You have been diagnosed with IBD (ulcerative colitis, Crohn's disease, or indeterminate colitis) for at least 3 months.
- Your IBD is moderate to severe despite trying at least one advanced therapy (like biologics) that didn't work or caused side effects.
- You have not had CAR-T or other cell therapy treatments before.
- You are not pregnant or breastfeeding and agree to use effective birth control during the study.
- You do not have any other active cancers, serious infections, or major health issues that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to calm down the immune attack that causes ulcerative colitis. It is for people with moderate to severe colitis who have not gotten better with standard medicines.
This early-phase trial is testing a patient-specific immune cell therapy (called CAR-T) for people with active ulcerative colitis or Crohn's disease. The therapy targets two proteins on immune cells to help calm the inflammation in the gut.
This study tests a new type of cell therapy called CAR-T cells that target three proteins (CD19, CD22, BCMA) to treat people with autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity.
This trial tests a new treatment called CAR-T cell therapy for people with severe autoimmune rheumatic diseases that have not improved with other treatments. The therapy uses your own immune cells, which are modified in a lab to attack the cells causing the disease, potentially reducing symptoms and improving quality of life.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
Hear when a new Inflammatory Bowel Diseases (IBD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.